Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.
Recent Posts
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
By Andrew Powaleny | May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...
Read More
A new era in Alzheimer’s innovation
By Andrew Powaleny | April 19, 2018
After heart disease and cancer, Alzheimer’s disease and dementia are the leading cause of death for seniors, responsible for one out of every three deaths. Today, the disease devastates the minds...
Read More
New report shows over 500 medicines in development for neurological disorders
By Andrew Powaleny | April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....
Read More
Rare Disease Day: Unmet need inspires innovation
By Andrew Powaleny | February 28, 2018
Today, we celebrate Rare Disease Day to both reflect on the progress made toward conquering rare diseases and recognize the continued unmet medical need for these devastating, complex conditions.
Read More
New report shows 200 medicines in development for heart disease and stroke
By Andrew Powaleny | February 20, 2018
Cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in the United States, accounting for one out of every three deaths. According to the American Heart...
Read More
ICYMI: Why 2017 medicine approvals matter
By Andrew Powaleny | January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...
Read More
ICYMI –Report highlights increasing prevalence for Alzheimer’s disease
By Andrew Powaleny | December 11, 2017
The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild...
Read More
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
By Andrew Powaleny | December 1, 2017
Today marks World AIDS Day, a moment to reflect on the significant advances made in the treatment and prevention of HIV, the virus which causes AIDS. The incredible scientific progress...
Read More
Supporting opportunities for enhanced competition in the marketplace
By Andrew Powaleny | November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...
Read More
Medicare Monday (100)
340B Spotlight (39)
Cost & Consequence (0)
